AstraZeneca and Daiichi Sankyo have claimed approval in the EU for Enhertu as a second-line therapy for HER2-positive metastatic breast cancer, moving the drug up the treatment pathway. The green ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results